07/07/2026
with and 💜
■ Prospective Validation of a FibroScan®-Based Stratification Algorithm for Advanced Liver Disease Detection in Patients with Type 2 Diabetes and MASLD in Diabetology Clinic
■ One-Year Changes in LSM by FibroScan® Device Predict Long-Term Liver Outcomes in Patients with MASLD: A Multicenter Cohort Study
■ Prospective Validation of a FibroScan®-Based Stratification Algorithm for Advanced Liver Disease Detection in Patients with Type 2 Diabetes and MASLD in Diabetology Clinic1
■ Systematic liver screening using FIB-4 and FibroScan® device in over 1,000 patients with type 2 diabetes revealed that 1 in 5 had clinically significant liver fibrosis, who were previously undiagnosed and at the rates far exceeding the general population.
■ These findings support routine implementation of the EASL-EASD algorithm in diabetology clinics as an effective tool to identify advanced liver disease and refer those patients to specialized care
■ One-Year Changes in LSM by FibroScan® Device Predict Long-Term Liver Outcomes in Patients with MASLD: A Multicenter Cohort Study2
■ Serial liver stiffness measurements by FibroScan® device prove that what happens to liver stiffness at 1 year determines what happens to the liver over the long term — a 1-year reduction in LSM cuts the risk of liver-related events by 47% and liver decompensation by 57%, while increases predict progressively worse outcomes.
■ As new MASLD drugs enter the market, this positions FibroScan® as the go-to non-invasive tool to monitor treatment response and guide the clinical decisions.
■ myBaveno: the new tool to help manage portal hypertension
• Interactive website with access to recommendations from Baveno VII publication
• A series of questions on a set of variables can be used to establish a recommendation
■ EASL-EASD-EASO Clinical Practice Guidelines
Management of MASLD
The EASL–EASD–EASO guidelines recommend VCTE®, our original and proprietary FibroScan® technology to measure liver stiffness with the specific cut-off value of 8 kPa in the stepwise strategy for non-invasive assessment of the risk for advanced fibrosis.
■ References:
1. Amiama, et al. Prospective validation of the EASL-EASD algorithm for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.
2. Pennisi, et al. One-year Changes in Liver Stiffness Measurement, but not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-term Liver Outcomes in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease.
Products in the FibroScan range are class IIa medical devices according to Rule 10 of ANNEX VIII of Regulation EU 2017/745 (CE 0459) and are manufactured by Echosens. FibroScan devices are intended to provide: Liver stiffness measurements at a shear wave frequency of 50 Hz, liver ultrasound attenuation measurements (CAP: Controlled Attenuation Parameter) at 3.5 MHz and spleen stiffness measurements at a shear wave frequency of 100 Hz (FibroScan 630 Expert only). These non-invasive devices are intended to aid clinical management, diagnosis, and monitoring of patients with confirmed or suspected chronic liver disease, as part of an overall assessment of the liver. FibroScan devices may aid the healthcare professionals in the assessment of liver fibrosis, steatosis, and in determining the likelihood of cirrhosis, and its complications (FibroScan 630 Expert only). They are used, in conjunction with other clinical and laboratory data, during liver assessment in patients with confirmed or suspected chronic liver disease. Examinations with FibroScan devices shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. Fast is a class IIa medical device according to Rule 11 of Annex VIII of Regulation EU 2017/745 (CE 0459). Agile 3+ and Agile 4 are class I medical devices according to Directive 93/42/EEC. Fast, Agile 3+ and Agile 4 are manufactured by Echosens. Fast is an algorithm intended to aid in the diagnosis of active fibrotic Non-Alcoholic Steatohepatitis (NASH) in patients with suspected Non-Alcoholic Fatty Liver Disease (NAFLD). Fast is used, during liver assessment, in patient with suspected NAFLD. The following precautions must be observed when using Fast: LSM (also known as E) and CAP measurements must come from the same FibroScan examination; There must be no more than 6 months between the FibroScan examination and the blood sample necessary for AST assessment. Fast must not be used in the following situations : pregnancy, patients under 18 years old, chronic or acute liver diseases other than NAFLD, liver transplant patients, cardiac failure and/or significant vascular disease, confirmed diagnosis of active malignancy or other terminal disease, use of treatment inducing liver injury. Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of NAFLD as having advanced fibrosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Agile 4 calculator is a tool for clinicians, computed from LSM (obtained from FibroScan device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of NAFLD as having cirrhosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Fast, Agile 3+ and Agile 4 are presented as educational services intended for licensed healthcare professionals. While these scores are about specific medical and health issues, they are not a substitute for or a replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. Users are expressly recommended to carefully read the instructions given in the user manual. User manual is available on the Score interface or Echosens website. To access, please make sure to be connected to the internet. FIB-4 index is a public tool developed by Sterling RK et al. (Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology 2006;43:1317-1325).
© 2026 Echosens, FibroScan and VCTE are trademarks owned by Echosens. All rights reserved.
myBaveno . myBaveno is a clinical decision support software intended to provide healthcare providers with relevant context about liver stiffness (E) measured by FibroScan® devices.
